PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Neurology and Brain Research Institute, University of Chicago, Chicago, IL, USA. areder@neurology.bsd.uchicago.edu.\', \'Laboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy.\', \'Unit of Neurology, IRCCS Neuromed, Pozzilli, Italy.\', \'Biogen, Cambridge, MA, USA.\', \'Biogen Idec, Maidenhead, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s40263-021-00804-1
?:hasPublicationType
?:journal
  • CNS drugs
is ?:pmid of
?:pmid
?:pmid
  • 33743151
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.635
?:rankingScore_hIndex
  • 96
is ?:relation_isRelatedTo_publication of
?:title
  • COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all